Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19.

Vityala, Yethindra; Tagaev, Tugolbai; Mamatov, Sagynali; Aidarov, Ziiabidin; Harinath, Panchadcharam

Vityala, Yethindra; Tagaev, Tugolbai; Mamatov, Sagynali; Aidarov, Ziiabidin; Harinath, Panchadcharam.

Vityala Y; Department of Pathology, International Higher School of Medicine, International University of Kyrgyzstan, Kyrgyzstan, China.
Tagaev T; Department of Public Health and Healthcare, I.K. Akhunbaev Kyrgyz State Medical Academy, Kyrgyzstan, China.
Mamatov S; Department of Hospital Internal Medicine, Occupational Pathology with a Course of Hematology, I.K. Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan, China.
Aidarov Z; Department of Public Health and Healthcare, I.K. Akhunbaev Kyrgyz State Medical Academy, Kyrgyzstan, China.
Harinath P; Department of Anatomy and Neuroscience, Jinzhou Medical University, Jinzhou, Liaoning, China.

Indian J Pharmacol ; 53(3): 246-247, 2021.

Article in English | MEDLINE | ID: covidwho-1282686

Subject(s)

Antibodies, Monoclonal, Humanized/administration & dosage; COVID-19 Drug Treatment; COVID-19/blood; Interleukin-6/antagonists & inhibitors; Interleukin-6/blood; Severity of Illness Index; Administration, Intravenous; Adult; Biomarkers/blood; Female; Follow-Up Studies; Humans; Male; Middle Aged; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severity of Illness Index / Interleukin-6 / Antibodies, Monoclonal, Humanized / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Prognostic study Limits: Adult / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Indian J Pharmacol Year: 2021 Document Type: Article Affiliation country: Ijp.IJP_33_21

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google